Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
Abstract Background Colorectal cancer (CRC) is the third most common cancer globally, with advanced stages presenting significant treatment challenges. Recently years, drug combination therapy has become a promising strategy for cancer treatment. Objective To evaluate the therapeutic efficacy of the...
Saved in:
Main Authors: | Ruohong Lin, Jiaxing Cheng, Jinlong Zhao, Liang Zhou, Jian Li, Xinchun Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2024-12-01
|
Series: | Journal of Cancer Research and Clinical Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1007/s00432-024-05984-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
by: Ritam Joarder, et al. -
Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
by: Toshiaki Takahashi, et al.
Published: (2025-01-01) -
Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01) -
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialResearch in context
by: Niels A.D. Guchelaar, et al.
Published: (2025-02-01) -
Hubungan antara Beban Tas dengan Risiko Skoliosis pada Siswa Kelas 4-6 Sekolah Dasar
by: Komang Trisna Handayani, et al.
Published: (2024-06-01)